Author: sugaradmin

Introduction and Objective: Early stage T1D screening programs in routine clinical care are in their infancy. With the availability of teplizumab, a disease-modifying therapy that delays progression to Stage 3 T1D, there is an urgent need to reimagine T1D care. Understanding current screening practices can inform implementation strategies and identify gaps as the field moves […]

Introduction and Objective: Prohormone convertase enzymes within α-cells process proglucagon into several peptides. These include glicentin (GLY), major proglucagon fragment (MPGF), and oxyntomodulin (OXM). Assessing their in vivo secretion (SR) can provide insights on α-cell function in health and disease. However, estimating their SR from peripheral concentrations requires knowledge of their kinetics. Here we propose […]

Introduction and Objective: This pilot study aimed to examine feasibility and acceptability of a telehealth DSMES intervention, Deaf Diabetes Can Together (DEDICATE), to support Deaf and hard of hearing (DHH) adults with type 1 and type 2 diabetes.Methods: Diabetes DHH Participants completed a 10- to 12-week multicomponent telehealth intervention in ASL consisting of DSMES ASL […]

Introduction and Objective: The quantification of plasma glucagon and oxytomodulin is important in the assessment of alpha-cell function, which is impaired in patients with diabetes. We aimed to develop, validate, and transfer between laboratories a novel assay that uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the sensitive and specific measurement of these highly homologous hormones.Methods: […]

Introduction and Objective: Islet allo-transplantation can potentially cure type 1 diabetes (T1D), but immune rejection and systemic immunosuppression remain key challenges. Inspired by cancer immunotherapy, we hypothesized that engineering islet cells with checkpoint ligands could induce transplant tolerance. Our lab previously showed that autologous β cells reverse autoimmunity in NOD mice. Here, we demonstrate proof […]

Introduction and Objective: Obesity is a chronic disease requiring lifelong management, yet peptide agonists face high discontinuation and rebound weight gain due to dosing burdens. Improving therapeutic persistence requires long-acting agents optimized for weight maintenance. Leveraging antibody-based half-life extension, we developed a potent GIPR antagonist. This study evaluates its cellular potency and metabolic durability in […]

Introduction and Objective: T1D & T2D Dysglycemia impairs intrinsic Mesenchymal Stromal Cells’ (MSCs) protective & regenerative functions including those of pancreatic Islet-intrinsic MSCs. This accelerates b-Cell loss. Replacing MSCs at high numbers within Neo-Islets (NIs) corrects the dysfunction. The MSC component in NIs exerts trophic, anti-inflammatory, auto- and allo-immune modulatory actions (survival, angiogenic, anti-fibrotic). We […]

Introduction and Objective: Real-world studies estimating the impact of substantial weight loss (WL) on vascular events in T2D are scarce. This retrospective cohort study investigated micro- and macrovascular risk after ≥15% WL in adults with newly diagnosed T2D.Methods: Adults with T2D and obesity were identified in UK primary care data from Clinical Practice Research Datalink […]